The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Mark Petrie is a Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and a cardiologist at Glasgow Royal Infirmary, UK. Professor Petrie has a high-volume clinical practice within a large heart failure team. His research interests focus on diabetes and cardiovascular disease, intervention in heart failure, subcutaneous furosemide in heart failure, revascularisation in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, cardiac remodelling, iron in heart failure and cardio-oncology. He has leadership roles in many trials including STICH, REVIVED, DAPA-HF, EMPACT-MI, STEP-HFpEF, REALIZE-K, IRONMAN, PARADISE-MI and has chaired or been a member of over 40 Clinical Events Committees for major trials. Mark has published over 220 original publications, many in high impact factor journals such as NEJM, Lancet, JAMA, Circulation and JACC.